@entity6 in @entity1 receiving @entity1140 in the post-transplant setting is rare. We describe two such cases in solid-organ transplant recipients. The first @entity1 , a 17-year-old male, presented with severe @entity6 and was managed with intravenous fluids and insulin infusion. He was a known case of @entity21160 and had received a renal transplant 2 years ago and was receiving @entity1140 since then. Although @entity6 resolved in 24 hours, large doses of subcutaneous insulin (upto 130 units per day) were needed to keep serum @entity413 within the normal range. Substitution of @entity1140 with @entity205 obviated the need for insulin or oral hypoglycaemics. The second @entity1 , a 55-year-old @entity1 , presented with a history of @entity2011 for 3 days. She had received a hepatic transplant 2 years ago and @entity1140 was being used since then. Mild @entity6 was managed with fluid resuscitation and subcutaneous insulin. Her insulin requirement after an uneventful recovery has been 54 - 70 units per day. Clinicians should be cognizant of the possibility of hyperglycaemic crisis presenting as sudden onset of @entity6 in @entity1 receiving @entity1140 . Use of an alternative @entity9909 may provide a safer solution to minimize future morbidity in such @entity1 .

XXXX associated with @entity1140 in solid organ transplant recipients.

@entity1 :: ('9606', 'Species') :: ['woman', 'patients', 'patient'] @entity21160 :: ('MESH:D020788', 'Disease') :: ['Laurence-Moon-Bardet-Biedl syndrome'] @entity2011 :: ('MESH:D011141', 'Disease') :: ['polyuria'] @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetic ketoacidosis', 'Diabetic ketoacidosis', 'diabetic ketocidosis'] @entity9909 :: ('23523', 'Gene') :: ['calcineurin inhibitor'] @entity205 :: ('MESH:D016572', 'Chemical') :: ['cyclosporine'] @entity1140 :: ('MESH:D016559', 'Chemical') :: ['tacrolimus'] @entity413 :: ('MESH:D005947', 'Chemical') :: ['glucose']
@entity6 :: (MESH:D003920,Disease) :: ['Diabetic ketoacidosis']
